Skip to Main Content

A patient advocacy group has filed a lawsuit to block the federal government from awarding an exclusive license to Gilead Sciences (GILD) for an experimental cancer therapy, arguing that the potential for a high price may preclude access to many Americans.

At issue is a CAR-T treatment, which relies on the immune system to attack cancer cells. Last December, the National Institutes of Health indicated plans to award a worldwide exclusive license to a CAR-T treatment that is being developed with taxpayer funds to Kite Pharma, which had recently been purchased by Gilead.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.